What is Metyos?
Metyos is a pioneering medtech startup dedicated to transforming the lives of chronic kidney disease (CKD) patients globally. The company has developed a sophisticated biowearable sensor coupled with a comprehensive disease management platform. This integrated technology provides continuous health monitoring, equipping both patients and healthcare professionals with the critical, real-time data necessary for informed decision-making and proactive treatment adjustments. Metyos's solution aims to significantly improve patient outcomes and streamline the management of this complex condition.
How much funding has Metyos raised?
Metyos has raised a total of $2.4M across 1 funding round:
Other Financing Round
$2.4M
Other Financing Round (2024): $2.4M with participation from Kima Ventures, Cenitz, and Banco BPI SA (France
Key Investors in Metyos
Kima Ventures
Kima Ventures is a highly active early-stage investor, known for backing approximately 100 startups annually from pre-seed to seed stages, providing crucial funding and network support.
Cenitz
CENITZ is a private equity firm specializing in early-stage healthcare companies and innovative startups, offering exclusive investment opportunities in sectors like medical devices and digital health.
Banco BPI SA (France
Bpifrance acts as a comprehensive resource for entrepreneurs, with a decentralized structure and a mission to support future-oriented ventures through extensive local support.
What's next for Metyos?
The recent major strategic investment signals a pivotal growth phase for Metyos. This infusion of capital is expected to accelerate the company's product development, expand its market reach, and further enhance its disease management platform. With a clear focus on innovation in the CKD space, Metyos is well-positioned to solidify its market leadership and continue its mission of empowering patients and clinicians with advanced technological solutions.
See full Metyos company page
